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Lessons From an Observational Study*John A. Bittl, MDSEE PAGE 1091T he goal of dual-antiplatelet therapy (DAPT) isto prevent local thrombotic complicationsrelated to stent implantation and to reduce
systemic atherothrombotic events. After implantation
of bare-metal stents, DAPT reduces stent thrombosis
by 85% (relative risk: 0.15; 95% conﬁdence interval
[CI]: 0.05 to 0.43) compared with aspirin alone
(1). After implantation of drug-eluting stents (DES),
DAPT for 30 months reduces stent thrombosis by 71%
(hazard ratio [HR]: 0.29; 95% CI: 0.17 to 0.48) and
late ischemic complications by 29% (HR: 0.71; 95% CI:
0.59 to 0.85) compared with DAPT for 12 months (2).
Because increased bleeding has been reported in
several randomized clinical trials (RCTs), the net
beneﬁt of long-term DAPT after stent implantation re-
mains uncertain and prolonged DAPT seems unlikely
to be lifesaving (3).
Beneﬁts of long-term DAPT may outweigh risks in
patients with diabetes mellitus, a condition associated
with vasculopathy, cardiomyopathy, nephropathy,
and suboptimal outcomes after percutaneous coro-
nary intervention (4). To study DAPT in a high-risk
population, Thukkani et al. (5), in this issue of the
Journal, completed an observational study within the
Veterans Administration health care system and
compared rates of death and myocardial infarction
(MI) in diabetic and nondiabetic cohorts deﬁned by
whether clopidogrel was used for >12 or #12 months
with aspirin after coronary stent implantation. As*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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relevant to the contents of this paper to disclose.reported by Thukkani et al. (5), the key ﬁndings were
lower rates of death (HR: 0.59; 95% CI: 0.48 to 0.92 for
insulin-dependent diabetic patients; HR: 0.61; 95% CI:
0.48 to 0.77 for non-insulin-dependent diabetic pa-
tients) and death or MI (HR: 0.67; 95% CI: 0.49 to 0.92
for insulin-dependent diabetic patients; HR: 0.61;
95% CI: 0.50 to 0.75 for non-insulin-dependent dia-
betic patients) when DAPT was used for 18 months
than when it was used for only 6 months after the
implantation of ﬁrst-generation DES.The study (5) was performed rigorously. Because
the results are provocative, it is important to deter-
mine whether they are supported by other evidence,
preferably from RCTs. A pooled analysis of the 7 RCTs
presenting a breakdown of diabetes mellitus results
(2,6–12) suggests that 12 to 30 months of DAPT
is no better than 3 to 12 months of DAPT after the
implantation of predominantly newer generation DES
(Figure 1). Discrepancies between the pooled analysis
(2,6–12) and the present study (5) in identifying the
beneﬁts of prolonged DAPT are attributed to differ-
ences in baseline risk, the type of stent used, and
fundamental differences in study design.
The present report (5) describes an observational
study that compared outcomes in patients whose
exposure to DAPT differed “naturally,” that is, not as
a result of random assignment, as in RCTs (13). In an
observational analysis, something other than chance
leads to early DAPT discontinuation and potentially
puts a subject in double jeopardy from stopping
therapy early and having an underlying condition
such as major surgery or bleeding, leading to platelet
activation and hyperﬁbrinogenemia.
Observational studies lack randomization, which
distributes the determinants of outcomes equally
FIGURE 1 Pooled Analysis of Diabetic Subgroups From Randomized Trials Comparing Prolonged With Short-Course DAPT
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1103between groups and prevents prognostic imbalance
from threatening the results (14). An observational
analysis should identify the reasons for stopping
treatment early (13). The Veterans Health Adminis-
tration investigators (5) were able to capture intra-
cranial and intraocular bleeding events in their
administrative database but were unable to identify
all the bleeding events or reasons why DAPT was
stopped at #12 months after stent implantation at a
time when evidence from RCTs supported the use of
DAPT for 1 year (15).
In an effort to account for differences between
the groups sorted by DAPT duration, the Veterans
Administration investigators used several statistical
adjustments, but patients who tolerated prolonged
DAPT and “passed a bleeding stress test” were argu-
ably different from those who stopped their medica-
tion early. The 2 groups had different outcomes,
and “adjustment” is unlikely to eliminate selection
bias (16).
This is not meant to be a criticism of a ﬁne obser-
vational study (5), but follow-up for the landmark
analyses seems to have been more complete for
patients who received DAPT for #12 months than for
those who continued for >12 months. Although a
common assumption is that patients who return for
follow-up have the same probabilities of death and MI
as those who are lost to follow-up, in a real-worldsetting, patients at high risk are followed more
intensely than those at low risk (17). Ideally an
observational study will record all relevant outcomes
for all study participants, and if the degree of ascer-
tainment is identical for both groups, bias will be
small to absent. If the degree of ascertainment differs
between groups, the risk for bias can threaten the
validity of the results (13).
The key ﬁnding of the present study (5), which
suggests that prolonged DAPT conferred a beneﬁt in
diabetic patients after DES implantation, is not
supported by the neutral ﬁndings for death or MI
in diabetic patients after bare-metal stent implan-
tation (HR: 0.88; 95% CI: 0.69 to 1.13 for insulin-
dependent diabetic patients; HR: 0.88; 95% CI:
0.75 to 1.03 for non-insulin-dependent diabetic pa-
tients), despite absolute event rates that were
higher than those after DES implantation. The
inability to show a beneﬁt after bare-metal stent
implantation or in several RCTs after newer-gener-
ation DES implantation (Figure 1) weakens sup-
port for prolonged DAPT for diabetic patients
undergoing stenting in current practice and em-
phasizes that observational studies, like philosophy,
although indispensable for interpreting contempo-
rary events, cannot change them. Before prolonged
DAPT can be routinely recommended for diabetic
patients undergoing stent implantation, additional
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1104investigation is needed to deﬁne the pathogenetic
links between the metabolic changes and clinical
manifestations of diabetes mellitus (4), and dedi-
cated clinical trials are needed to identify best
practices.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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